Ipsen (XPAR:IPN) LT-Debt-to-Total-Asset : 0.04 (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Ipsen LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Ipsen's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.04.

Ipsen's long-term debt to total assets ratio declined from Dec. 2022 (0.10) to Dec. 2023 (0.04). It may suggest that Ipsen is progressively becoming less dependent on debt to grow their business.

Ipsen LT-Debt-to-Total-Asset Historical Data

The historical data trend for Ipsen's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipsen LT-Debt-to-Total-Asset Chart

Ipsen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.16

0.15

0.13

0.10

0.04

Ipsen Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.13	0.12	0.10	0.06	0.04

Ipsen LT-Debt-to-Total-Asset Calculation

Ipsen's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	269.7	/	6322.9
	=	0.04

Ipsen's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	269.7	/	6322.9
	=	0.04

Ipsen (XPAR:IPN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Ipsen LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Ipsen's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Ipsen (XPAR:IPN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (XPAR:IPN) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

IPSEY:USA IPSEF:USA 0MH6:UK I7G:Germany

Address

65 Quai Georges Gorse, Billancourt Cedex, Boulogne, FRA, 92100

Website

https://www.ipsen.com

Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.